{
  "id": 20285205,
  "title": "STAT+: Pharmalittle: We’re reading about GLP-1 use, Covid-19 vaccine investment returns, and more",
  "url": "https://urgent.news/2026/11/16/stat-pharmalittle-were-reading-about-glp-1-use-covid-19-vaccine",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-16T14:17:01.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/pharmalot/2026/11/16/glp1-use-covid-19-vaccines-return-on-investment/"
  },
  "original_language": "en",
  "account": "Good morning and welcome to another work week. After the weekend break, the familiar cycle of deadlines, online meetings, and phone calls returns. The world keeps turning and it's up to us to contribute positively. Our recommendation for the day is pistachio. Please feel free to join in.\n\nHere are a few noteworthy points to kick off your day. According to the Centers for Disease Control and Prevention, in July and August 2025, roughly one in ten U.S. adults reported using a GLP-1 medication within the past year. Among those using GLP-1 medicines, about one in five used a compounded version, while 9% were unsure if their medication was indeed compounded. This uncertainty highlights the challenges in differentiating compounded versions from FDA-approved drugs.\n\nMany GLP-1 users altered their usage in response to prescribed instructions, often due to cost and availability issues. The pharmaceutical industry is calling for an audit of the World Health Organization's expenditures using funds contributed by drugmakers for pandemic preparedness. The International Federation of Pharmaceutical Manufacturers is lobbying for one of the Big 4 accounting firms to audit these industry contributions to the WHO’s Pandemic Influenza Preparedness Framework. Some manufacturers are even withholding contributions. However, the WHO maintains that it already has an external auditor and that all funds are spent in compliance with its regulations. For more details, continue reading STAT+.",
  "summary": "During July and August 2025, approximately 1 in 10 U.S. adults reported taking a GLP-1 medication during the previous year",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}